Literature DB >> 20024540

Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP.

Meghan Bushway1, Kelly A Cycon, Kathleen Mulvaney, Shawn P Murphy.   

Abstract

Loss of major histocompatibility complex class II (MHCII) antigen expression on diffuse large B cell lymphoma (DLBCL) corresponds closely with significant decreases in patient survival. However, the mechanisms accounting for MHCII loss in DLBCL have not been thoroughly characterized to date. In this report, we demonstrate that coordinate loss of MHCII expression in OCI-Ly2 DLBCL cells is associated with an 11-base deletion in the cDNA encoding RFX-AP, one of the subunits of the heterotrimeric regulatory factor X (RFX) that is required for activating MHCII transcription. This deletion results in a frameshift in the RFX-AP protein beginning at amino acid 234 and, therefore, in the loss of C-terminal amino acids that are required for function. Stable transfection of OCI-Ly2 DLBCL cells with an expression vector for wild-type RFX-AP restores MHCII expression, which strongly suggests that the defect in RFX-AP accounts for MHCII loss in these cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20024540     DOI: 10.1007/s00251-009-0418-3

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  33 in total

Review 1.  Genetic control of MHC class II expression.

Authors:  Jenny Pan-Yun Ting; John Trowsdale
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

2.  Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP.

Authors:  M Peretti; J Villard; E Barras; M Zufferey; W Reith
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

3.  Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.

Authors:  Lisa M Rimsza; Robin A Roberts; Elias Campo; Thomas M Grogan; Silvia Bea; Itziar Salaverria; Andreas Zettl; Andreas Rosenwald; German Ott; H Konrad Muller-Hermelink; Jan Delabie; Richard I Fisher; Joseph M Unger; Michael Leblanc; Louis M Staudt; Elaine S Jaffe; Randy D Gascoyne; Wing C Chan; Dennis D Weisenburger; Timothy Greiner; Rita M Braziel; Thomas P Miller
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

4.  Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course.

Authors:  S M Lippman; C M Spier; T P Miller; D J Slymen; J A Rybski; T M Grogan
Journal:  Mod Pathol       Date:  1990-05       Impact factor: 7.842

5.  Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors.

Authors:  W J Magner; A L Kazim; C Stewart; M A Romano; G Catalano; C Grande; N Keiser; F Santaniello; T B Tomasi
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

6.  RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency.

Authors:  B Durand; P Sperisen; P Emery; E Barras; M Zufferey; B Mach; W Reith
Journal:  EMBO J       Date:  1997-03-03       Impact factor: 11.598

7.  Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence.

Authors:  A F List; C M Spier; T P Miller; T M Grogan
Journal:  Leukemia       Date:  1993-03       Impact factor: 11.528

Review 8.  [Primary mediastinal large B-cell lymphoma:a report of 24 cases with literature review].

Authors:  Dao-Guang Chen; Yu Yang; Cai-Zhu Pan
Journal:  Ai Zheng       Date:  2008-02

9.  Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts.

Authors:  Renae Holtz; Jason C Choi; Margaret G Petroff; Janet F Piskurich; Shawn P Murphy
Journal:  Biol Reprod       Date:  2003-05-14       Impact factor: 4.285

10.  Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma.

Authors:  Robin A Roberts; Constantine M Sabalos; Michael L LeBlanc; Ralph R Martel; Yvette M Frutiger; Joseph M Unger; Ihab W Botros; Matthew P Rounseville; Bruce E Seligmann; Thomas P Miller; Thomas M Grogan; Lisa M Rimsza
Journal:  Lab Invest       Date:  2007-08-13       Impact factor: 5.662

View more
  4 in total

Review 1.  Dysfunction of antigen processing and presentation by dendritic cells in cancer.

Authors:  Joanna Bandola-Simon; Paul A Roche
Journal:  Mol Immunol       Date:  2018-04-05       Impact factor: 4.407

2.  Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.

Authors:  Kelly A Cycon; Kathleen Mulvaney; Lisa M Rimsza; Daniel Persky; Shawn P Murphy
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

3.  A pan-cancer modular regulatory network analysis to identify common and cancer-specific network components.

Authors:  Sara A Knaack; Alireza Fotuhi Siahpirani; Sushmita Roy
Journal:  Cancer Inform       Date:  2014-10-28

4.  Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation.

Authors:  Guoping Ding; Xiaodong Xu; Dan Li; Yuhao Chen; Weimin Wang; Dongnan Ping; Shengnan Jia; Liping Cao
Journal:  Cell Death Dis       Date:  2020-10-22       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.